SEC Form 4 · accession 0001140361-15-004133
SALIX PHARMACEUTICALS LTD · SLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alonzo Thomas D
Officer — Acting Chief Executive Officer · Director
Period of report
Feb 2, 2015
Accepted (ET)
Feb 4, 2015 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001009356
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 2, 2015 | A | 14,662 | $0.00 | A | 95,587 | D | |
| Common StockF2 | holding | — | — | — | 10,450 | I | By Trust | |
| Common StockF3 | holding | — | — | — | 1,080 | I | By Trust | |
| Common Stock | holding | — | — | — | 260 | I | By LP | |
| Common Stock | holding | — | — | — | 6,500 | I | By Wife |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Buy Common StockF4 | $17.63 | holding | — | — | — | — | Jun 9, 2015 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1Represents a restricted stock award of which one-half will vest on each of the six-month anniversary and the twelve-month anniversary of the grant date, subject to Mr. D'Alonzo's continued employment as Acting Chief Executive Officer of the Issuer.
- F2The shares are held by the Thomas W. D'Alonzo Rev Trust U/A DTD 10/24/2001 for which the Reporting Person serves as co-trustee.
- F3The shares are held by the Rachel L. D'Alonzo Rev Trust U/A DTD 10/24/2001 for which the Reporting Person serves as co-trustee.
- F4Options are 100% vested.